Abstract

Consortium Funds ($750,000). The consortium funding component is utilized to provide reimbursement at the research base as well as at North Central Cancer Treatment Group member sites not having their own CCOP grant. This funding is provided at the rate specified by the NIH; currently $2,000 per case credit, and is restricted to capitation reimbursement for cancer control protocols. Predicting the total funding needed for this component of the grant is dependent on numerous variables such as new protocols coming on-line, closing of existing protocols, and the accrual activity of participating sites. Funding is requested for this submission to support 375 total accruals at all non-CCOP NCCTG sites at the current rate of $2,000 each, for a total request of $750,000.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA037404-22
Application #
7515885
Study Section
Special Emphasis Panel (ZCA1-SRRB-3 (J1))
Project Start
2007-09-14
Project End
2012-05-31
Budget Start
2007-09-14
Budget End
2008-05-31
Support Year
22
Fiscal Year
2007
Total Cost
$825,700
Indirect Cost

  Institution

Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905

  Publications

Barton, Debra L; Sloan, Jeff A; Shuster, Lynne T et al. (2018) Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer 26:643-650
Foster, Jared C; Le-Rademacher, Jennifer G; Feliciano, Josephine L et al. (2017) Comparative ""nocebo effects"" in older patients enrolled in cancer therapeutic trials: Observations from a 446-patient cohort. Cancer 123:4193-4198
Himelstein, Andrew L; Foster, Jared C; Khatcheressian, James L et al. (2017) Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA 317:48-58
Schild, Steven E; Hillman, Shauna L; Tan, Angelina D et al. (2017) Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non-Small Cell Lung Cancer: NCCTG N0028 (Alliance). J Thorac Oncol 12:697-703
Bhatia, Aarti K; Lee, Ju-Whei; Pinto, Harlan A et al. (2017) Double-blind, randomized phase 3 trial of low-dose 13-cis retinoic acid in the prevention of second primaries in head and neck cancer: Long-term follow-up of a trial of the Eastern Cooperative Oncology Group-ACRIN Cancer Research Group (C0590). Cancer 123:4653-4662
Liu, Xiaonan; Li, Jing; Schild, Steven E et al. (2017) Statins and Metformin Use Is Associated with Lower PSA Levels in Prostate Cancer Patients Presenting for Radiation Therapy. J Cancer Ther 8:73-85
Kottschade, Lisa; Novotny, Paul; Lyss, Alan et al. (2016) Chemotherapy-induced nausea and vomiting: incidence and characteristics of persistent symptoms and future directions NCCTG N08C3 (Alliance). Support Care Cancer 24:2661-7
Sio, Terence T; Atherton, Pamela J; Birckhead, Brandon J et al. (2016) Repeated measures analyses of dermatitis symptom evolution in breast cancer patients receiving radiotherapy in a phase 3 randomized trial of mometasone furoate vs placebo (N06C4 [alliance]). Support Care Cancer 24:3847-55
Atherton, Pamela J; Burger, Kelli N; Pederson, Levi D et al. (2016) Patient-reported outcomes questionnaire compliance in Cancer Cooperative Group Trials (Alliance N0992). Clin Trials 13:612-620
Miller, Robert C; Petereit, Daniel G; Sloan, Jeff A et al. (2016) N08C9 (Alliance): A Phase 3 Randomized Study of Sulfasalazine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy. Int J Radiat Oncol Biol Phys 95:1168-74

Showing the most recent 10 out of 377 publications